Wedbush lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $63 from $64 and keeps an Outperform rating on the shares. Following completion of the upsized $748M secondary offering, the firm is incorporating the raise into its estimates.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Xenon Sets Date for 2026 Annual Shareholder Meeting
- Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors
- Xenon Strengthens Balance Sheet With Major Equity Offering
- Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00
- Xenon Raises $650 Million in Upsized U.S. Equity Offering